Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus

Annals of the Rheumatic Diseases

Volumn 61, Issue 12, 2002, Pages 1065-1070

  Manger, Karin ^a   Manger, B ^a   Repp, R ^a   Geisselbrecht, M ^a   Geiger, A ^a   Pfahlberg, A ^a   Harrer, T ^a   Kalden, J R ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; COMPLEMENT COMPONENT C3; CRYOGLOBULIN; DNA ANTIBODY; LUPUS ANTICOAGULANT; RIBONUCLEOPROTEIN ANTIBODY; RO ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE CLEARANCE; DATA BASE; DISEASE ACTIVITY; EUROPE; FEMALE; HUMAN; HYPERTENSION; INFECTION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MEDICAL SOCIETY; MORTALITY; NEPHRITIS; ONSET AGE; OUTPATIENT DEPARTMENT; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTECTION; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; SEROLOGY; SEX DIFFERENCE; SPLENOMEGALY; SURVIVAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOEMBOLISM; TREATMENT OUTCOME;

ADULT; AGE FACTORS; CENTRAL NERVOUS SYSTEM DISEASES; COHORT STUDIES; CREATININE; FEMALE; HEART DISEASES; HUMANS; KIDNEY FAILURE, CHRONIC; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MULTIVARIATE ANALYSIS; NEPHRITIS; RISK FACTORS; SEX FACTORS; THROMBOEMBOLISM;

EID: 0036892104     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.61.12.1065     Document Type: Article

References (50)

1. Hartung K, Baur MP, Coldewey R, Fricke M, Kalden JR, Lakomek HJ, et al. Major histocompatibility complex haplotypes and complement C4 alleles in systemic lupus erythematosus. Results of a multicenter study. J Clin Invest 1992;90:1346-51.
2. Manger K, Repp R, Spriewald BM, Rascu A, Geiger A, Wassmuth R, et al. Fcgamma receptor IIa polymorphism in Caucasian patients with systemic lupus erythematosus: Association with clinical symptoms. Arthritis Rheum 1998;41:1181-9.
3. Rascu A, Repp R, Westerdaal NA, Kalden JR, van de Winkel JG. Clinical relevance of Fc gamma receptor polymorphisms. Ann NY Acad Sci 1997;815:282-95.
4. Tan FK, Arnett FC. The genetics of lupus. Curr Opin Rheumatol 1998;10:399-408.
5. Harley JB, Moser KL, Goffney PM, Behrens TW. The genetics of human systemic lupus erythematosus. Curr Opin Immunol 1998;10:690-6.
6. Criswell LA, Amos CI. Update on genetic risk factors for systemic lupus erythematosus and rheumatoid arthritis. Curr Opin Rheumatol 2000;12:85-90.
7. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus [see comments]. Arthritis Rheum 1996;39:363-9.
8. Vitali C, Bencivelli W, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, et al. Disease activity in systemic lupus erythematosus: Report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 1992;10:541-7.
9. Bencivelli W, Vitali C, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, et al. Disease activity in systemic lupus erythematosus: Report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 1992;10:549-54.
10. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
11. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter] [see comments]. Arthritis Rheum 1997;40:1725.
12. Hahn B. Systemic lupus erythematosus. In: Fauci AS BE, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, et al, eds. Harrison's Principles of Internal Medicine. New York: McGraw Hill, Vol 2, 1998:1876.
13. Kaplan EL MP. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-9.
14. Kleinbaum G. Survival Analysis: A Self Learning Text. Vol 1. New York: Springer, 1986.
15. Cox Dr O. Analysis of Survival Data. Vol 1. New York: Chapman and Hall, 1984.
16. Bailar JI, Mosteller F. Medical uses of statistics. In: Waltham M, ed: Boston: N Engl J Med Books, 1986.
17. Urowitz MB, Gladman DD, Abu-Shakra M, Farewell VT. Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24 years. J Rheumatol 1997;24:1061-5.
18. Gladman DD. Prognosis and treatment of systemic lupus erythematosus. Curr Opin Rheumatol 1995;7:402-8.
19. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol 1995;22:1259-64.
20. Gripenberg M, Helve T. Outcome of systemic lupus erythematosus. A study of 66 patients over 7 years with special reference to the predictive value of anti-DNA antibody determinations. Scand J Rheumatol 1991;20:104-9.
21. Seleznick MJ, Fries JF. Variables associated with decreased survival in systemic lupus erythematosus. Semin Arthritis Rheum 1991;21:73-80.
22. Stahl-Hallengren C, Jansen A, Nived O, Sturfelt G. Incidence studies of systemic lupus erythematosus in southern Sweden: Increasing age, decreasing frequency of renal manifestations and good prognosis. J Rheumatol 2000;27:685-91.
23. Jacobsen S, Petersen J, Ullman S, Junker P, Voss A, Rasmussen JM, et al. Mortality and causes of death of 513 Danish patients with systemic lupus erythematosus. Scand J Rheumatol 1999;28:75-80.
24. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976;60:221-5.
25. Kiss E, Regeczy N, Szegedi G. Systemic lupus erythematosus survival in Hungary. Results from a single centre. Clin Exp Rheumatol 1999;17:171-7.
26. Urowitz MB, Gladman DD. How to improve morbidity and mortality in systemic lupus erythematosus. Rheumatology (Oxford) 2000;39:238-44.
27. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study. Am J Epidemiol 1997;145:408-15.
28. Mok CC, Lee KW, Ho CT, Lau CS, Wong RW. A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population. Rheumatology (Oxford) 2000;39:399-406.
29. Kim WU, Min JK, Lee SH, Park SH, Cho CS, Kim HY. Causes of death in Korean patients with systemic lupus erythematosus: A single center retrospective study. Clin Exp Rheumatol 1999;17:539-45.
30. Ward MM, Studenski S. Systemic lupus erythematosus in men: A multivariate analysis of gender differences in clinical manifestations. J Rheumatol 1990;17:220-4.
31. Blanco FJ, Gomez-Reino JJ, de la Mata J, Corrales A, Rodriguez-Valverde V, Rosas JC, et al. Survival analysis of 306 European Spanish patients with systemic lupus erythematosus. Lupus 1998;7:159-63.
32. Jonsson H, Nived O, Sturfelt G. Outcome in systemic lupus erythematosus: A prospective study of patients from a defined population. Medicine (Baltimore) 1989;68:141-50.
33. Swaak AJ, Nossent JC, Bronsveld W, Van Rooyen A, Nieuwenhuys EJ, Theuns L, et al. Systemic lupus erythematosus. I. Outcome and survival: Dutch experience with 110 patients studied prospectively. Ann Rheum Dis 1989;48:447-54.
34. Reveille JD, Bartolucci A, Alarcon GS. Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death. Arthritis Rheum 1990;33:37-48.
35. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1999;78:167-75.
36. Jacobsen S, Petersen J, Ullman S, Junker P, Voss A, Rasmussen JM, et al. A multicentre study of 513 Danish patients with systemic lupus erythematosus. II. Disease mortality and clinical factors of prognostic value. Clin Rheumatol 1998;17:478-84.
37. Baker SB, Rovira JR, Campion EW, Mills JA. Late onset systemic lupus erythematosus. Am J Med 1979;66:727-32.
38. Swaak AJ, van Den Brink HG, Smeenk RJ, Manger K, Kalden JR, Tosi S, et al. Systemic lupus erythematosus: Clinical features in patients with a disease duration of over 10 years, first evaluation. Rheumatology (Oxford) 1999;38:953-8.
39. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Fortin P, Ginzler E, et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) damage index for systemic lupus erythematosus international comparison. J Rheumatol 2000;27:373-6.
40. Stoll T, Seifert B, Isenberg DA. SLICC/ACR damage index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol 1996;35:248-54.
41. Jonsson H, Nived O, Sturfelt G, Silman A. Estimating the incidence of systemic lupus erythematosus in a defined population using multiple sources of retrieval [see comments]. Br J Rheumatol 1990;29:185-8.
42. Vitali C, Bencivelli W, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, et al. Disease activity in systemic lupus erythematosus: Report of the Consensus Study Group of the European Workshop for Rheumatology Research. I. A descriptive analysis of 704 European lupus patients. European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 1992;10:527-39.
43. Derksen RH, Hene RJ, Kater L. The long-term clinical outcome of 56 patients with biopsy-proven lupus nephritis followed at a single center. Lupus 1992;1:97-103.
44. Stone JH. End-stage renal disease in lupus: Disease activity, dialysis, and the outcome of transplantation. Lupus 1998;7:654-9.
45. Abraham MA, Korula A, Jayakrishnan K, John GT, Thomas PP, Jacob CK. Prognostic factors in diffuse proliferative lupus nephritis. J Assoc Physicians India 1999;47:862-5.
46. Jacobsen S, Starklint H, Petersen J, Ullman S, Junker P, Voss A, et al. Prognostic value of renal biopsy and clinical variables in patients with lupus nephritis and normal serum creatinine. Scand J Rheumatol 1999;28:288-99.
47. Xie SK, Feng SF, Fu H. Long term follow-up of patients with systemic lupus erythematosus. J Dermatol 1998;25:367-73.
48. Petri M. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins lupus cohort [in process citation]. Lupus 2000;9:170-5.
49. Horbach DA, van Oort E, Donders RC, Derksen RH, de Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies [see comments]. Thromb Haemost 1996;76:916-24.
50. Mok CC, Lau CS, Wong RW. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum 1998;41:831-7.